2022/09/30 | Research | Artificial Intelligence
An artificial intelligence system for brain tumor segmentation from multisequence MRI has received 510k clearance by the US American Food and Drug Administration on 29 September 2022. The system was developed by Prof. Dr. Mauricio Reyes and his team from the Medical Image Analysis lab, at the ARTORG Center and the Center of AI in Medicine, Univ. of Bern. Work on this important milestone by many talented PhD and Master students has started at the @MICCAI 2011 conference, receiving the 2016 MICCAI Young Scientist Publication Impact Award as well as the 2016 Ypsomed Innovation Award. It underlines the importance of Bernese research on a global scale.
“It´s great to know that specialists in the field can now have clinical access to the technology. The collaboration with the colleagues at Neosoma had been amazing and a privilege for me as scientist. For our team this is also recognition for years of interdisciplinary and translationally oriented research with our clinical collaborators for this important clinical need," says Prof. Dr. Mauricio Reyes, head of the Medical Image Analysis group at the University of Bern, and first developer of the system.
Media release by Neosoma, 29 September 2022